Treatment of COVID‐19 induced chilblains with topical nitroglycerin

International Journal of DermatologyVolume 59, Issue 12 p. 1522-1524 Case report Treatment of COVID-19 induced chilblains with topical nitroglycerin Mark Weingarten BA, Mark Weingarten BA Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USASearch for more papers by this authorBrian Abittan MD, Brian Abittan MD Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USASearch for more papers by this authorRyan Rivera-Oyola MS, Corresponding Author Ryan Rivera-Oyola MS [email protected] orcid.org/0000-0002-1855-2511 Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA Correspondence Ryan Rivera-Oyola, ms 5 East 98th Street, 5th Floor New York, NY 10029 USA E-mail: [email protected]Search for more papers by this authorAbraham I. Abittan MD, Abraham I. Abittan MD Department of Dermatology, Comprehensive Dermatology, Woodmere, NY, USASearch for more papers by this authorMichael Weingarten BA, Michael Weingarten BA Department of Dermatology, State University of New York Upstate Medical University, Syracuse, NY, USASearch for more papers by this authorMark Lebwohl MD, Mark Lebwohl MD Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USASearch for more papers by this author Mark Weingarten BA, Mark Weingarten BA Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USASearch for more papers by this authorBrian Abittan MD, Brian Abittan MD Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USASearch for more papers by this authorRyan Rivera-Oyola MS, Corresponding Author Ryan Rivera-Oyola MS [email protected] orcid.org/0000-0002-1855-2511 Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA Correspondence Ryan Rivera-Oyola, ms 5 East 98th Street, 5th Floor New York, NY 10029 USA E-mail: [email protected]Search for more papers by this authorAbraham I. Abittan MD, Abraham I. Abittan MD Department of Dermatology, Comprehensive Dermatology, Woodmere, NY, USASearch for more papers by this authorMichael Weingarten BA, Michael Weingarten BA Department of Dermatology, State University of New York Upstate Medical University, Syracuse, NY, USASearch for more papers by this authorMark Lebwohl MD, Mark Lebwohl MD Department of Dermatology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USASearch for more papers by this author First published: 20 October 2020 https://doi.org/10.1111/ijd.15253Citations: 3 Conflict of interest: Dr. Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Eli Lilly, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron-Sanofi, and UCB, Inc. He has been the principal investigator for numerous clinical trials but has no personal financial gain. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Galván Casas C, Català A, Carretero Hernández G, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol 2020; 183: 71–77. 10.1111/bjd.19163 CASPubMedWeb of Science®Google Scholar 2Jia JL, Kamceva M, Rao SA, et al. Cutaneous manifestations of COVID-19: a preliminary review. J Am Acad Dermatol 2020; 83: 687–690. 10.1016/j.jaad.2020.05.059 CASPubMedWeb of Science®Google Scholar 3Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020; 383: 120–128. 10.1056/NEJMoa2015432 CASPubMedWeb of Science®Google Scholar 4Kolivras A, Dehavay F, Delplace D, et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathologic findings. JAAD Case Rep 2020; 6: 489–492. 10.1016/j.jdcr.2020.04.011 PubMedGoogle Scholar 5Poor HD, Ventetuolo CE, Tolbert T, et al. COVID-19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis. Clin Transl Med 2020; 10: e44. 10.1002/ctm2.44 PubMedWeb of Science®Google Scholar 6Dowd PM, Rustin MH, Lanigan S. Nifedipine in the treatment of chilblains. Br Med J (Clin Res Ed) 1986; 293: 923–924. 10.1136/bmj.293.6552.923-a CASPubMedWeb of Science®Google Scholar 7Ganor S. Corticosteroid therapy for pernio. J Am Acad Dermatol 1983; 8: 136. 10.1016/S0190-9622(83)80309-0 CASPubMedWeb of Science®Google Scholar 8Shahi V, Wetter DA, Cappel JA, et al. Vasospasm is a consistent finding in pernio (chilblains) and a possible clue to pathogenesis. Dermatology 2015; 231: 274–279. 10.1159/000437224 PubMedWeb of Science®Google Scholar 9Takci Z, Vahaboglu G, Eksioglu H. Epidemiological patterns of perniosis, and its association with systemic disorder. Clin Exp Dermatol 2012; 37: 844–849. 10.1111/j.1365-2230.2012.04435.x CASPubMedWeb of Science®Google Scholar 10Nyssen A, Benhadou F, Magnée M, et al. Chilblains. Vasa 2020; 49: 133–140. 10.1024/0301-1526/a000838 PubMedWeb of Science®Google Scholar 11Rustin MH, Newton JA, Smith NP, et al. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol 1989; 120: 267–275. 10.1111/j.1365-2133.1989.tb07792.x CASPubMedWeb of Science®Google Scholar 12Souwer IH, Bor JH, Smits P, et al. Nifedipine vs placebo for treatment of chronic chilblains: a randomized controlled trial. Ann Fam Med 2016; 14: 453–459. 10.1370/afm.1966 PubMedWeb of Science®Google Scholar 13Verma P. Topical nitroglycerine in perniosis/chilblains. Skinmed 2015; 13: 176–177. PubMedGoogle Scholar Citing Literature Volume59, Issue12December 2020Pages 1522-1524 This article also appears in:International Journal of Dermatology COVID-19 Papers ReferencesRelatedInformation